 |
| |
 |
| |
 |
| |
 |
| |
 |
| _____________________________________________________________________________________________________________________ © 2005-11 All Rights Reserved. NOD Pharmaceuticals, Inc. |
SAN DIEGO & SHANGHAI, April 30, 2006 /For Immediate Release/ -- NOD Pharmaceuticals,
Inc. announced the investigational new drug application (IND) for its oral insulin project (Nodlin)
has been filed with Chinese State Food & Drug Administration (SFDA).
"It is a significant milestone achievement for NOD Pharmaceuticals and its operation arm, Shanghai
Biolaxy," quoted from William Lee, CEO of NOD Pharmaceuticals. "IND filing for Nodlin is a major
step forward for the company and its project development."
Nodlin is an oral insulin formulation to replace insulin injections many diabetic patients have to
endure during their life time. It is estimated that there are 30-40 million diabetic patients in China
with 1.2 million new cases each year.
NOD Pharmaceuticals is a biopharmaceutical company focusing on oral delivery of macromolecular
drugs such as insulin and interferon. NOD Pharmaceuticals uses proprietary nano-particle oral
delivery or NOD technology to develop oral formulations of biopharmaceutical products.
SOURCE NOD Pharmaceuticals, Inc.
William Lee, Ph.D, CEO of NOD Pharmaceuticals, Inc., +1-858-717-0332
URL http://www.nodpharm.com
Email info@nodpharm.com
Inc. announced the investigational new drug application (IND) for its oral insulin project (Nodlin)
has been filed with Chinese State Food & Drug Administration (SFDA).
"It is a significant milestone achievement for NOD Pharmaceuticals and its operation arm, Shanghai
Biolaxy," quoted from William Lee, CEO of NOD Pharmaceuticals. "IND filing for Nodlin is a major
step forward for the company and its project development."
Nodlin is an oral insulin formulation to replace insulin injections many diabetic patients have to
endure during their life time. It is estimated that there are 30-40 million diabetic patients in China
with 1.2 million new cases each year.
NOD Pharmaceuticals is a biopharmaceutical company focusing on oral delivery of macromolecular
drugs such as insulin and interferon. NOD Pharmaceuticals uses proprietary nano-particle oral
delivery or NOD technology to develop oral formulations of biopharmaceutical products.
SOURCE NOD Pharmaceuticals, Inc.
William Lee, Ph.D, CEO of NOD Pharmaceuticals, Inc., +1-858-717-0332
URL http://www.nodpharm.com
Email info@nodpharm.com
Press Release
| IND Filed for Oral Insulin in China |
 |  |  |
-Innovation Delivered